

DAFTAR PUSTAKA

1. Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, et al. Rheumatoid Arthritis: A Brief Overview of the Treatment. Medical Principles and Practice. Biomedicines. 2018;27(6):501–7.
2. Mitrović J, Hrkač S, Tečer J, Golob M, Ljilja Posavec A, Kolar Mitrović H, et al. Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis—A Comprehensive Review. Biomedicines. 2023;11(5):1262.
3. Venetsanopoulou AI, Alamanos Y, Voulgari P V., Drosos AA. Epidemiology and Risk Factors for Rheumatoid Arthritis Development. Mediterr J Rheumatol. 2023;34(4):404.
4. Kementerian Kesehatan Republik Indonesia. Hasil Utama RISKESDAS 2018. Jakarta; 2018.
5. Suryana BPP, Hidayat R, Sarmidi S, Wibowo SAK, Hamijoyo L, Rahmadi AR, et al. Characteristics and prevalence of clinical remission of rheumatoid arthritis in a nationwide study from Indonesia. Int J Rheum Dis. 2024;27(2):1–8.
6. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463–71.
7. Cai Y, Zhang J, Liang J, Xiao M, Zhang G, Jing Z, et al. The Burden of Rheumatoid Arthritis: Findings from the 2019 Global Burden of Diseases Study

and Forecasts for 2030 by Bayesian Age-Period-Cohort Analysis. *J Clin Med*. 2023;12(4):1291.

8. Zhang F, Jonsson AH, Nathan A, Millard N, Curtis M, Xiao Q, et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. *Nature*. 2023;623(7987):616–24.
9. Vincze A, Bodoki L, Szabó K, Nagy-Vincze M, Szalmás O, Varga J, et al. The risk of fracture and prevalence of osteoporosis is elevated in patients with idiopathic inflammatory myopathies: cross-sectional study from a single Hungarian center. *BMC Musculoskelet Disord*. 2020;21(1):426.
10. Raterman HG, Bultink IE, Lems WF. Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention. *Expert Opin Pharmacother*. 2020;21(14):1725–37.
11. Salliot C, Nguyen Y, Boutron-Ruault MC, Seror R. Environment and Lifestyle: Their Influence on the Risk of RA. *J Clin Med*. 2020;9(10):3109.
12. van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. *J Autoimmun*. 2020;110:102392.
13. Llorente I, García-Castañeda N, Valero C, González-Álvaro I, Castañeda S. Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons. *Front Med (Lausanne)*. 2020;7:601618.
14. Sakthiswary R, Uma Veshaliini R, Chin KY, Das S, Sirasanagandla SR. Pathomechanisms of bone loss in rheumatoid arthritis. *Front Med (Lausanne)*. 2022;9:692969.

15. Coury F, Peyruchaud O, Machuca-Gayet I. Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases. *Front Immunol.* 2019;10:679.
16. Terkawi MA, Matsumae G, Shimizu T, Takahashi D, Kadoya K, Iwasaki N. Interplay between Inflammation and Pathological Bone Resorption: Insights into Recent Mechanisms and Pathways in Related Diseases for Future Perspectives. *Int J Mol Sci.* 2022;23(3):1786.
17. Inam Illahi M, Amjad S, Alam SM, Ahmed ST, Fatima M, Shahid MA. Serum Tumor Necrosis Factor-Alpha as a Competent Biomarker for Evaluation of Disease Activity in Early Rheumatoid Arthritis. *Cureus.* 2021;13(5):e15314.
18. Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, et al. Interleukin 1 α : a comprehensive review on the role of IL-1 α in the pathogenesis and treatment of autoimmune and inflammatory diseases. *Autoimmun Rev.* 2021;20(3):102763.
19. Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. *Nat Rev Rheumatol.* 2019;15(10):612–32.
20. Takeuchi T, Yoshida H, Tanaka S. Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. *Autoimmun Rev.* 2021;20(9):102884.
21. Yokota K, Sato K, Miyazaki T, Aizaki Y, Tanaka S, Sekikawa M, et al. Characterization and Function of Tumor Necrosis Factor and Interleukin-6- Induced Osteoclasts in Rheumatoid Arthritis. *Arthritis Rheumatol.* 2021;73(7):1145–54.
22. Fardellone P, Séjourné A, Paccou J, Goëb V. Bone Remodelling Markers in Rheumatoid Arthritis. *Mediators Inflamm.* 2014;2014:1–5.

23. Chauhan K, Jandu JS, Brent LH, Al-Dhahir MA. Rheumatoid Arthritis. [Updated 2023 May 25]. In: StatPearls [Internet]. Treasure Island [FL]: StatPearls Publishing; 2024.
24. Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. *Lancet Rheumatol*. 2023;5(10):e594–610.
25. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. *Rheumatol Int*. 2021;41(5):863–77.
26. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. *Nat Rev Dis Primers*. 2018;4(1):18001.
27. Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. *Nat Immunol*. 2021;22(1):10–8.
28. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. *Best Pract Res Clin Rheumatol*. 2017;31(1):3–18.
29. Alpízar-Rodríguez D, Pluchino N, Canny G, Gabay C, Finckh A. The role of female hormonal factors in the development of rheumatoid arthritis. *Rheumatology*. 2017;56(8):1254–63.
30. Petrovská N, Prajzlerová K, Vencovský J, Šenolt L, Filková M. The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. *Autoimmun Rev*. 2021;20(5):102797.

31. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis. JAMA. 2018;320(13):1360–72.
32. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6(1):15.
33. Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy. Biomedicine & Pharmacotherapy. 2017;92:615–33.
34. Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, et al. The Role of Tumor Necrosis Factor Alpha (TNF- α) in Autoimmune Disease and Current TNF- α Inhibitors in Therapeutics. Int J Mol Sci. 2021;22(5):2719.
35. Migliorini P, Italiani P, Pratesi F, Puxeddu I, Boraschi D. The IL-1 family cytokines and receptors in autoimmune diseases. Autoimmun Rev. 2020;19(9):102617.
36. Favalli EG. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol Ther. 2020;7(3):473–516.
37. Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127–48.
38. Erickson AR, Cannella AC, Mikuls TR. Clinical Features of Rheumatoid Arthritis. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR, Kozetzky G, editors. Kelley and Firestein's Textbook of Rheumatology. 10th ed.

Elsevier; 2017.(3) 1167–86.



39. Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. *Autoimmun Rev.* 2021;20(4):102776.
40. Taylor PC. Update on the diagnosis and management of early rheumatoid arthritis. *Clinical Medicine.* 2020;20(6):561–4.
41. Van Hoovels L, Studenic P, Sieghart D, Steiner G, Bossuyt X, Rönnelid J. Impact of autoimmune serology test results on RA classification and diagnosis. *J Transl Autoimmun.* 2022;5:100142.
42. Kgoebane K, Ally MMTM, Duim-Beytell MC, Suleman FE. The role of imaging in rheumatoid arthritis. *South African Journal of Radiology.* 2018;22(1):1316.
43. Sahbudin I, Pickup L, Nightingale P, Allen G, Cader Z, Singh R, et al. The role of ultrasound-defined tenosynovitis and synovitis in the prediction of rheumatoid arthritis development. *Rheumatology.* 2018;57(7):1243–52.
44. Hidayat R, Suryana BP, Wijaya LK, Ariane A, Hellmi RY, Adnan E, et al. *Diagnosis dan Pengelolaan Artritis Reumatoid.* Jakarta; 2021.
45. Weddell J, Hider S. Diagnosis and management of rheumatoid arthritis. *Prescriber.* 2021;32(10):15–20.
46. Metsios GS, Brodin N, Vlieland TPMV, Van den Ende CHM, Stavropoulos-Kalinoglou A, Fatouros I, et al. Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit. *Mediterr J Rheumatol.* 2021;32(4):378.
47. Metsios GS, Fenton SA, Moe HR, van der Esch M, van Zanten JV, Koutedakis Y, et al. Implementation of Physical Activity into routine Clinical practice in

Rheumatic Musculoskeletal Disease: The IMPACT-RMD study protocol and rationale. *Mediterr J Rheumatol*. 2019;30(4):231.

48. Jahid M, Khan KU, Rehan-Ul-Haq, Ahmed RS. Overview of Rheumatoid Arthritis and Scientific Understanding of the Disease. *Mediterr J Rheumatol*. 2023;34(3):284.
49. Marketos N, Bournazos I, Ioakimidis D. Canakinumab for refractory RA: a case report. *Mediterr J Rheumatol*. 2018;29(3):170–2.
50. Kim JW, Suh CH. Systemic Manifestations and Complications in Patients with Rheumatoid Arthritis. *J Clin Med*. 2020;9(6):2008.
51. Le B, Nurcombe V, Cool S, Van Blitterswijk C, De Boer J, LaPointe V. The Components of Bone and What They Can Teach Us about Regeneration. *Materials*. 2017;11(1):14.
52. Ralston SH. Bone structure and metabolism. *Medicine*. 2021;49(9):567–71.
53. Šromová V, Sobola D, Kaspar P. A Brief Review of Bone Cell Function and Importance. *Cells*. 2023;12(21):2576.
54. Saladin KS. Bone Tissue. In: Gan CA, editor. *Anatomy & Physiology: The Unity of Form and Function*. 10th ed. New York: McGraw Hill; 2024. (2). 196–220.
55. Ponzetti M, Rucci N. Osteoblast Differentiation and Signaling: Established Concepts and Emerging Topics. *Int J Mol Sci*. 2021;22(13):6651.
56. Tresguerres FGF, Torres J, López-Quiles J, Hernández G, Vega JA, Tresguerres IF. The osteocyte: A multifunctional cell within the bone. *Annals of Anatomy - Anatomischer Anzeiger*. 2020;227:151422.

57. McDonald MM, Kim AS, Mulholland BS, Rauner M. New Insights Into Osteoclast Biology. *JBM R Plus*. 2021;5(9):10539.
58. Hu K, Shang Z, Yang X, Zhang Y, Cao L. Macrophage Polarization and the Regulation of Bone Immunity in Bone Homeostasis. *J Inflamm Res*. 2023;16:3563–80.
59. Zhao T, Chu Z, Ma J, Ouyang L. Immunomodulation Effect of Biomaterials on Bone Formation. *J Funct Biomater*. 2022;13(3):103.
60. Bolamperti S, Villa I, Rubinacci A. Bone remodeling: an operational process ensuring survival and bone mechanical competence. *Bone Res*. 2022;10(1):48.
61. Kenkre J, Bassett J. The bone remodelling cycle. *Annals of Clinical Biochemistry: International Journal of Laboratory Medicine*. 2018;55(3):308–27.
62. Hart NH, Newton RU, Tan J, Rantalainen T, Chivers P, Siafarikas A, et al. Biological basis of bone strength: anatomy, physiology and measurement. *J Musculoskelet Neuronal Interact*. 2020;20(3):347–71.
63. Gasser JA, Kneissel M. Bone Physiology and Biology. In: Smith SY, Varela A, Samadfam R, editors. *Bone Toxicology*. 1st ed. Springer; 2017. (1). 27–94.
64. Kim JM, Lin C, Stavre Z, Greenblatt MB, Shim JH. Osteoblast-Osteoclast Communication and Bone Homeostasis. *Cells*. 2020;9(9):2073.
65. Ming J, Cronin SJF, Penninger JM. Targeting the RANKL/RANK/OPG Axis for Cancer Therapy. *Front Oncol*. 2020;10(1283):1–13.

66. Tobeiha M, Moghadasian MH, Amin N, Jafarnejad S. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. *Biomed Res Int*. 2020;2020:1–11.
67. De Leon-Oliva D, Barrena-Blázquez S, Jiménez-Álvarez L, Fraile-Martinez O, García-Montero C, López-González L, et al. The RANK–RANKL–OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer. *Medicina (B Aires)*. 2023;59(10):1752.
68. Guder C, Gravius S, Burger C, Wirtz DC, Schildberg FA. Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System. *Front Immunol*. 2020;11:58.
69. Auréal M, Machuca-Gayet I, Coury F. Rheumatoid Arthritis in the View of Osteoimmunology. *Biomolecules*. 2020;11(1):48.
70. Yang M, Zhu L. Osteoimmunology: The Crosstalk between T Cells, B Cells, and Osteoclasts in Rheumatoid Arthritis. *Int J Mol Sci*. 2024;25(5):2688.
71. Andreev D, Kachler K, Schett G, Bozec A. Rheumatoid arthritis and osteoimmunology: The adverse impact of a deregulated immune system on bone metabolism. *Bone*. 2022;162:116468.
72. Okamoto K, Takayanagi H. Osteoimmunology. *Cold Spring Harb Perspect Med*. 2019;9(1):a031245.
73. Mun SH, Park PSU, Park-Min KH. The M-CSF receptor in osteoclasts and beyond. *Exp Mol Med*. 2020;52(8):1239–54.
74. Kurotaki D, Yoshida H, Tamura T. Epigenetic and transcriptional regulation of osteoclast differentiation. *Bone*. 2020;138:115471.

75. Humphrey MB, Nakamura MC. A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts. *Clin Rev Allergy Immunol*. 2016;51(1):48–58.
76. Maranini B, Bortoluzzi A, Silvagni E, Govoni M. Focus on Sex and Gender: What We Need to Know in the Management of Rheumatoid Arthritis. *J Pers Med*. 2022 Mar;12(3):499.
77. Hughes GC, Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. *Nat Rev Rheumatol*. 2014 Dec;10(12):740–51.
78. Kovacs WJ, Olsen NJ. Sexual dimorphism of RA manifestations: genes, hormones and behavior. *Nat Rev Rheumatol*. 2011 May;7(5):307–10.
79. Petta I, Peene I, Elewaut D, Vereecke L, De Bosscher K. Risks and benefits of corticosteroids in arthritic diseases in the clinic. *Biochem Pharmacol*. 2019 Jul;165:112–25.
80. Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). *Ann Rheum Dis*. 2013 Feb;72(2):204–10.
81. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis*. 2023 Jan;82(1):3–18.
82. Rubio-Romero E, Díaz-Torné C, Moreno-Martínez MJ, De-Luz J. Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes. *BMC Rheumatol*. 2024 Mar;8(1):11.

83. Shin S, Park EH, Kang EH, Lee YJ, Song YW, Ha YJ. Sex differences in clinical characteristics and their influence on clinical outcomes in an observational cohort of patients with rheumatoid arthritis. *Joint Bone Spine*. 2021 May;88(3):105124.
84. Fadda S, Hamdy A, Abulkhair E, Mahmoud Elsify H, Mostafa A. Serum levels of osteoprotegerin and RANKL in patients with rheumatoid arthritis and their relation to bone mineral density and disease activity. *The Egyptian Rheumatologist*. 2015 Jan;37(1):1–6.
85. Ljung L, Rantapää-Dahlqvist S. Abdominal obesity, gender and the risk of rheumatoid arthritis – a nested case-control study. *Arthritis Res Ther*. 2016 Dec;18(1):277.
86. Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q, et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. *Arthritis Res Ther*. 2015 Mar;17(1):86.
87. Feng X, Xu X, Shi Y, Liu X, Liu H, Hou H, et al. Body Mass Index and the Risk of Rheumatoid Arthritis: An Updated Dose-Response Meta-Analysis. *Biomed Res Int*. 2019 Jul;2019:1–12.
88. Hussein R, Aboukhamis I. The association of serum RANKL levels with disease activity and hematological parameters in Syrian patients with rheumatoid arthritis. *Biochem Biophys Rep*. 2022 Dec;32:101373.
89. Burska AN, El-Jawhari JJ, Wu J, Wakefield RJ, Marzo-Ortega H, Conaghan PG, et al. Receptor activator of nuclear factor kappa-B ligand (RANKL) serum levels

are associated with progression to seropositive/negative rheumatoid arthritis. Clin Exp Rheumatol. 2021 May;39(3):456–62.

90. Shrivastava AK, Singh HV, Raizada A, Singh SK, Pandey A, Singh N, et al. Inflammatory markers in patients with rheumatoid arthritis. Allergol Immunopathol (Madr). 2015 Jan;43(1):81–7.
91. Meyer PWA, Hodgkinson B, Ally M, Musenge E, Wadee AA, Fickl H, et al. Circulating Cytokine Profiles and Their Relationships with Autoantibodies, Acute Phase Reactants, and Disease Activity in Patients with Rheumatoid Arthritis. Mediators Inflamm. 2010;2010:1–10.
92. Ruscitti P, Cipriani P, Carubbi F, Liakouli V, Zazzeroni F, Di Benedetto P, et al. The Role of IL-1 β in the Bone Loss during Rheumatic Diseases. Mediators Inflamm. 2015 Jan;2015(1).
93. Osiri M, Wongpiyabovorn J, Sattayasomboon Y, Thammacharoenrach N. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics. Clin Rheumatol. 2016 Jul;35(7):1673–81.
94. Milman N, Karsh J, Booth RA. Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem. 2010 Nov;43(16–17):1309–14.
95. Luo G, Li F, Li X, Wang Z, Zhang B. TNF- α and RANKL promote osteoclastogenesis by upregulating RANK via the NF- κ B pathway. Mol Med Rep. 2018 Mar;

96. Marahleh A, Kitaura H, Ohori F, Kishikawa A, Ogawa S, Shen WR, et al. TNF- α Directly Enhances Osteocyte RANKL Expression and Promotes Osteoclast Formation. *Front Immunol.* 2019 Dec;10.
97. Steeve KT, Marc P, Sandrine T, Dominique H, Yannick F. IL-6, RANKL, TNF- α /IL-1: interrelations in bone resorption pathophysiology. *Cytokine Growth Factor Rev.* 2004 Feb;15(1):49–60.
98. Yokota K, Sato K, Miyazaki T, Kitaura H, Kayama H, Miyoshi F, et al. Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. *Front Immunol.* 2021;12:836192.
99. Ansalone C, Ucciardello C, Contino L, Ambrosio MR, Tripodo C, Ciccia F, et al. TNF-mediated epigenetic downregulation of the transcription factor RANK in CD14⁺ monocytes inhibits osteoclastogenesis. *J Autoimmun.* 2021;119:102611.
100. Steeve KT, Marc P, Sandrine T, Dominique H, Yannick F. IL-6, RANKL, TNF- α /IL-1: Interrelations in bone resorption pathophysiology. *Cytokine Growth Factor Rev.* 2004;15(1):49-60
101. Takayanagi H. Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. *Nat Rev Immunol.* 2007;7(4):292-304
102. Lv H, Tang Y, Zhang Z, Li S, Fan Z, Fan H, et al. Effects of anti-RANKL antibody on the expression of inflammatory cytokines in collagen-induced arthritis model rats. *Arch Rheumatol.* 2023;38(4):446-53.

103. Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. *Arthritis Res Ther*. 2002;4(Suppl 3):S281-9.
104. Yokota K, Sato K, Miyazaki T, Kitaura H, Kayama H, Miyoshi F, et al. Tumor necrosis factor α and interleukin-6 synergistically induce osteoclast differentiation via NFAT and JAK pathways. *Immunopharmacol Immunotoxicol*. 2024;46(2):120-30.
105. Papadaki HA, Eliopoulos AG. RANKL signaling and osteoclastogenesis: Emerging therapeutic targets in arthritis. *Front Immunol*. 2019;10:97.
106. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. *Arthritis Rheum*. 2000;43(2):250-8.
107. O'Gradaigh D, Ireland D, Bord S, Compston JE. Joint erosion in rheumatoid arthritis: Interactions between tumour necrosis factor α , interleukin 1, and receptor activator of nuclear factor κ B ligand (RANKL) regulate osteoclasts. *Ann Rheum Dis*. 2004;63(4):354-9.
108. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- α and IL-17. *Rheumatology (Oxford)*. 2008;47(11):1635-40.